Value through Innovation17 January 2013

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 next

10.06.2009	New data once more show high therapeutic benefits of Boehringer Ingelheim`s Mirapexin®/Sifrol® (pramipexole) once-daily extended release formulation, also in patients with advanced Parkinson`s disease - For medical media, outside the US only
06.06.2009	New data from Boehringer Ingelheim`s ongoing linagliptin trial programme show promising safety and efficacy results - For medical media, outside the US only
29.05.2009	Boehringer Ingelheim and DxS sign an agreement for a companion diagnostic to identify EGFR mutations in patients with lung cancer
27.05.2009	Boehringer Ingelheim and the World Stroke Organization announce partnership in the World Stroke Academy - For medical media, outside the US only
15.05.2009	Boehringer Ingelheim to present new phase II clinical data on two lead oncology compounds at ASCO 2009 - For medical media, outside the US only
13.05.2009	Boehringer Ingelheim and DeveloGen AG announce agreement in the field of diabetes, obesity and the metabolic syndrome
08.05.2009	Exelixis and Boehringer Ingelheim enter into collaboration for development of S1P1 receptor agonists in the field of autoimmune diseases
30.04.2009	Outcome of new Mirapexin®/ Sifrol® (pramipexole) study set to change treatment of depressive symptoms in Parkinson`s disease - For medical media, outside the US only
29.04.2009	New study results support once daily, prolonged release formulation of Mirapexin®/ Sifrol®(pramipexole) for the treatment of Parkinson`s disease - For medical media, outside the US only
28.04.2009	No increased risk of treatment-induced augmentation in Restless Legs Syndrome (RLS) demonstrated in long-term placebo-controlled study with Mirapexin®/ Sifrol® (pramipexole) - For medical media, outside the US only
21.04.2009	Boehringer Ingelheim maintains its growth path in 2008, again growing faster than the pharmaceutical market - major investments once again in Research and Development - good outlook for further growth in 2009
23.03.2009	The European Porcine-Circovirus-Research-Award honours scientists from Denmark, France and Netherlands
20.03.2009	Boehringer Ingelheim`s novel oral anticoagulant dabigatran etexilate is the frontrunner for stroke prevention in atrial fibrillation: final patient completes treatment in the RE-LY® study, the largest atrial fibrillation outcomes trial to date - For medical media, outside the US only
19.03.2009	Experts unite to create new online resource for Restless Legs Syndrome - For medical media, outside the US only
03.03.2009	New diagnostic tool helps health care professionals accurately diagnose Hypoactive Sexual Desire Disorder (HSDD) in women - For medical media, outside the US only
06.02.2009	Boehringer Ingelheim Foundation makes huge investment in cutting-edge research at the Johannes Gutenberg University of Mainz
30.01.2009	Duloxetine significantly reduced osteoarthritis knee pain in new study
28.01.2009	ECASS 3 study receives recognition from the European Stroke Organisation and The Lancet - For medical media, outside the US only

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 next

Media Contact

Our media contacts

Page content

Boehringer Ingelheim Press Releases

Press Release Archive

Media Contact

Further Media Channels

Other News & Press Releases